John A.  Bartholdson net worth and biography

John Bartholdson Biography and Net Worth

Director of Bioventus

John Bartholdson is the co-founder and partner of Juniper Investment Company, LLC, a private investment management firm investing in publicly traded companies and private companies through concentrated ownership positions. His significant governance, finance, and transactional experience with multiple public and private companies make him active on several other boards and committees.  

Mr. Bartholdson presently serves as the Chairman of the board of directors of Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets. Since 2019, he has been a member of the board of directors of Lincoln Educational Services Corporation, a public company and a leading provider of career education and training services, and presently serves on its Compensation, Audit and Nominating and Corporate Governance Committees. He also served as a member of the board of directors of Obagi Medical Products, Inc., a public specialty pharmaceutical company, until its acquisition by Valeant Pharmaceuticals in 2013.  

Mr. Bartholdson was a Partner of Stonington Partners. Prior to that, he was an analyst at Merrill Lynch Capital Partners. He received his B.A. from Duke University and his M.B.A. from Stanford Graduate School of Business. 

What is John A. Bartholdson's net worth?

The estimated net worth of John A. Bartholdson is at least $52.68 million as of August 16th, 2024. Bartholdson owns 6,913,857 shares of Bioventus stock worth more than $52,683,590 as of December 4th. This net worth approximation does not reflect any other investments that Bartholdson may own. Learn More about John A. Bartholdson's net worth.

How do I contact John A. Bartholdson?

The corporate mailing address for Bartholdson and other Bioventus executives is 4721 EMPEROR BOULEVARD SUITE 100, DURHAM NC, 27703. Bioventus can also be reached via phone at 919-474-6700 and via email at [email protected]. Learn More on John A. Bartholdson's contact information.

Has John A. Bartholdson been buying or selling shares of Bioventus?

John A. Bartholdson has not been actively trading shares of Bioventus in the last ninety days. Most recently, on Monday, August 19th, John A. Bartholdson bought 25,500 shares of Bioventus stock. The stock was acquired at an average cost of $8.55 per share, with a total value of $218,025.00. Following the completion of the transaction, the director now directly owns 6,939,357 shares of the company's stock, valued at $59,331,502.35. Learn More on John A. Bartholdson's trading history.

Who are Bioventus' active insiders?

Bioventus' insider roster includes John Bartholdson (Director), Katrina Church (SVP), Robert Claypoole (CEO), Anthony D'Adamio (SVP), P III (CEO), Kenneth Reali (CEO), Mark Singleton (Sr. VP), and Mark Singleton (CFO). Learn More on Bioventus' active insiders.

Are insiders buying or selling shares of Bioventus?

In the last twelve months, insiders at the sold shares 10 times. They sold a total of 83,963 shares worth more than $759,143.60. The most recent insider tranaction occured on November, 7th when Director Michelle Mcmurry-Heath sold 17,701 shares worth more than $131,341.42. Insiders at Bioventus own 33.0% of the company. Learn More about insider trades at Bioventus.

Information on this page was last updated on 11/7/2025.

John A. Bartholdson Insider Trading History at Bioventus

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/19/2024Buy25,500$8.55$218,025.006,939,357View SEC Filing Icon  
8/16/2024Buy80,000$8.55$684,000.006,913,857View SEC Filing Icon  
8/10/2023Buy111,848$4.47$499,960.566,768,835View SEC Filing Icon  
6/14/2023Buy181,946$3.24$589,505.046,546,807View SEC Filing Icon  
6/12/2023Buy395,401$2.92$1,154,570.926,304,537View SEC Filing Icon  
5/22/2023Buy178,998$2.08$372,315.845,909,136View SEC Filing Icon  
5/19/2023Buy1,136,675$1.94$2,205,149.505,730,138View SEC Filing Icon  
See Full Table

John A. Bartholdson Buying and Selling Activity at Bioventus

This chart shows John A Bartholdson's buying and selling at Bioventus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bioventus Company Overview

Bioventus logo
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $7.62
Low: $7.47
High: $7.64

50 Day Range

MA: $7.07
Low: $6.51
High: $7.79

2 Week Range

Now: $7.62
Low: $5.81
High: $11.89

Volume

251,591 shs

Average Volume

375,268 shs

Market Capitalization

$630.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79